The Drugs for Neglected Diseases initiative (DNDi) has issued a call for nominations for a new Board member with high-level experience in pharmaceutical research and development (R&D) and/or academia relating to scientific research.
DNDi is an independent, not-for-profit foundation registered under the Swiss Civil Code, administered by a Board of Directors (the Board). Board members are experts in their field and are chosen for their commitment to the public interest, their technical competency, and their support of the mission of DNDi. The Board has powers over all matters pertaining to DNDi, notably, approving the overall policies and principles of DNDi, including those related to ethical considerations and fundraising strategies; approving project selection; and adopting the annual work plan and budget.
Board members are selected from areas of expertise including (but not limited to) pharma/biotech research and development and related science, business development, clinical development, public health, fundraising, finance, legal, and global health communications and advocacy. The Board currently has 12 members. The Board is seeking to enhance its competencies with the addition of a Board member with high-level experience in pharmaceutical R&D and/or academia relating to scientific research. Further information is included in the Terms of Reference.
Board memberships are for a term of four years and a maximum of three consecutive terms (12 years total). Board members serve in an honorary capacity and are allowed reimbursement for reasonable expenses related to their work with DNDi, including travel expenses.
The closing date for applications is 26 February 2020.
About DNDi
Established in 2003, the Drugs for Neglected Diseases initiative (DNDi) is a not-for-profit R&D organization that develops new, improved, and affordable medicines for deadly neglected diseases that afflict millions of the world’s poorest people. DNDi focuses on discovering and developing treatments for sleeping sickness (human African trypanosomiasis), Chagas disease, leishmaniasis, filarial infections, paediatric HIV, mycetoma, and hepatitis C. Since its inception, DNDi has developed seven new treatments for neglected patients and has developed a robust R&D pipeline including new drug candidates. www.dndi.org
